Abstracts tagged "Uric Acid, Urate"

Abstract Number: 1990 • ACR Convergence 2025
Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout
Alex Tinianow¹, Saiajay Chigurupati¹, Ethan Carey¹, Jiaqi Wang², Sharan Rai³, Gregory Challener⁴, Hyon K. Choi⁵, Philip Riches⁶, Natalie McCormick¹ and Chio Yokose⁷, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, BOston, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴MGH, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶NHS Lothian, Edinburgh, UK, Edinburgh, United Kingdom, ⁷Massachusetts General Hospital, Waltham, MA
Background/Purpose: Rheumatology guidelines endorse a treat-to-target (TTT) approach targeting serum urate (SU) < 6 mg/dL among patients with gout who qualify for urate-lowering therapy (ULT).…
Abstract Number: 1991 • ACR Convergence 2025
Co-Use of Mycophenolate Mofetil with Pegloticase Yielded Similar Clinical Outcomes as the Co-Use of Methotrexate
Tingting Zhang¹, Kenneth Saag², Yasir Qazi³, Bradley Marder⁴ and Brian Lamoreaux⁵, ¹Amgen, Inc., Thousand Oaks, ²The University of Alabama at Birmingham, Birmingham, AL, ³Keck School of Medicine Renal Transplant Program, University of Southern California, Los Angeles, CA, ⁴AMGEN, Inc, Denver, CO, ⁵Amgen, Inc., Deerfield, IL
Background/Purpose: Pegloticase significantly reduces serum uric acid (sUA) values in patients with refractory gout. Co-use of methotrexate (MTX) improves efficacy and safety of pegloticase by…
Abstract Number: 1923 • ACR Convergence 2025
A Real-World Survey On Physicians’ Perspectives Of Uncontrolled Gout And Gout Management Practices.
John Botson¹, Menaka Bhor², Nathan Meyer², Molly Edwards³, Emily Goddard³, Victoria Barton⁴ and Jeff Peterson⁵, ¹Orthopedic Physicians of Alaska, Anchorage, AK, ²Sobi Inc, Waltham, MA, ³Adelphi Real World, Bollington, United Kingdom, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Western Washington Arthritis Clinic, Bothell, WA
Background/Purpose: Managing uncontrolled gout (UG) can involve a multi-disciplinary approach involving physicians of different specialities, all of whom may have differing perspectives or approaches for…
Abstract Number: 1139 • ACR Convergence 2025
Synovial Counts, Cultures, and Crystals: An Analysis of 9,000 Aspirations
Sabahat Usmani¹, Gunjan Rana², Shivum Patel¹, Patrick Kennedy¹ and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, ²Saint Vincent Hospital, Worcester, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Synovial fluid analysis is an essential diagnostic tool for evaluating crystalline and infectious arthritis. Traditionally, a leukocyte count threshold of >50,000 cells/µL has been…
Abstract Number: 1138 • ACR Convergence 2025
Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi
Robert Keenan¹, Puja Khanna², Zancong Shen³, Sarah Morris³, Pamela Mundell⁴, Wen Wei⁴, Elizabeth Polvent⁵, Vijay Hingorani⁶, Shunqi Yan⁵ and Li-Tain Yeh⁷, ¹Arthrosi Therapeutics, Raleigh, NC, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Arthrosi therapeutics, San Diego, CA, ⁴Arthrosi Therapeutics Inc, San Diego, CA, ⁵Arthrosi Therapeutics, Inc., San Diego, CA, ⁶Vanguard Healthsciences, Inc., San Diego, CA, ⁷Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: Pozdeutinurad (AR882, POZD) is a novel, selective URAT1 inhibitor currently in phase 3 clinical stage development for the treatment of gout and tophaceous gout.…
Abstract Number: L05 • ACR Convergence 2024
Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels
Christian Schwabe¹, Orit Cohen Barak², Alexandra Cole³, Hadar Reuveni², Liron Shelev², Liora Blinder-Haddad² and Nicola Dalbeth⁴, ¹NZCR, Auckland, New Zealand, ²Protalix Ltd, Karmiel, Israel, ³NZCR, Christchurch, New Zealand, ⁴University of Auckland, Auckland, New Zealand
Background/Purpose: PEGylated uricases have already demonstrated therapeutic modality in the treatment of refractory gout patients. PRX-115 is a recombinant homotetrameric uricase enzyme, produced from Candida…
Abstract Number: 0907 • ACR Convergence 2024
Association of Rare and Common Genetic Variants in MOCOS with Inadequate Response to Allopurinol
Niamh Fanning¹, Murray Cadzow², Ruth Topless³, Chris Frampton⁴, Nicola Dalbeth⁵, Tony Merriman⁶ and Lisa Stamp⁴, ¹University of Otago, Christchurch, New Zealand, ²University of Otago, Dunedin 9054, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of Alabama at Birmingham, Homewood, AL
Background/Purpose: The minor allele of the common rs2231142 (Q141K) ABCG2 variant predicts inadequate response to allopurinol urate lowering therapy (ULT). We hypothesize that additional variants in genes…
Abstract Number: 2560 • ACR Convergence 2024
Continuous Reduction in Ultrasound Detected Crystal Depositions over 5 Years Follow-up: Results from the NOR-Gout Study
Hilde B Hammer¹, Lars F Karoliussen¹, Lene Terslev², Espen A. Haavardsholm³ and Tillmann Uhlig¹, ¹Diakonhjemmet hospital, Oslo, Norway, ²Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, ³Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway
Background/Purpose: Ultrasound (US) is sensitive for detecting monosodium urate (MSU) crystal depositions in gout, described as double contour (DC), tophi and aggregates. Depositions decreased during…
Abstract Number: 1085 • ACR Convergence 2024
Pharmacokinetics and Pharmacodynamics of Tigulixostat in Participants with Mild, Moderate, and Severe Renal Impairment
Ashish Kumar¹, Ali Hariri¹, Yunjung Lee² and Minhyung Lee², ¹LG Chem Life Sciences USA, Boston, MA, ²LG Chem, Seoul, Republic of Korea
Background/Purpose: Tigulixostat is a potent and highly selective non-purine based xanthine oxidase inhibitor (XOi) being investigated for the management of hyperuricemia in patients with gout.…
Abstract Number: 1090 • ACR Convergence 2024
Hepatic Fibrosis Before and During Intensive Urate-lowering with Pegloticase in the Presence and Absence of Methotrexate Co-therapy
Naomi Schlesinger¹, Katie Obermeyer², Lissa Padnick-Silver², Brian LaMoreaux³ and Peter Lipsky⁴, ¹University of Utah, Salt Lake City, UT, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen, Inc., Deerfield, IL, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Gout is associated with non-alcoholic fatty liver disease (NAFLD),1 with elevated serum urate (SU) and high flare frequency (≥3 flares/yr) contributing.2 The Fib-4 index, calculated from…
Abstract Number: 1091 • ACR Convergence 2024
Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study
Chamaya De Silva¹, César Díaz², Gregory Gamble³, Anne Horne³, Anthony Doyle³, Lisa Stamp⁴ and Nicola Dalbeth³, ¹Health NZ Waitemata, Auckland, New Zealand, ²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: In gout, monosodium urate (MSU) crystal deposition occurs preferentially at certain joints, most frequently the first metatarsophalangeal (MTP) joint. Dual energy CT (DECT) allows…
Abstract Number: 1878 • ACR Convergence 2024
The Associations Between Gout and Ischemic Colitis Among Hospitalized Patients: A Retrospective Nationwide Analysis
Nidaa Rasheed¹, Humzah Iqbal², SRIKAR SAMA³ and candice reyes⁴, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³University of California San Francisco Fresno, Fresno, CA, ⁴VACCHCS, Fresno, CA
Background/Purpose: Gout is the most common form of inflammatory arthropathy. It occurs due to urate crystal deposition within the joint space, usually in the setting…
Abstract Number: 1885 • ACR Convergence 2024
Effect of Physical Activity on Mortality in Rheumatoid Arthritis: A Dose-Response Analysis
Bo Chen¹ and Qibing Xie², ¹Chenbo, Chendu, Sichuan, China, ²Department of Rheumatology and Immunology, Chengdu, Sichuan, China
Background/Purpose: Patients with Rheumatoid arthritis (RA) tend to perform less physical activity compared to the recommended guidelines. The long-term effects of physical activity on mortality…
Abstract Number: 1898 • ACR Convergence 2024
Hyperuricemia Is Associated with Higher Levels of Fasting Plasma Glucose and Insulin Resistance in Non-diabetic Subjects
Janis Timsans¹, Jenni Kauppi¹, Anne Kerola², Vappu Rantalaiho³, Hannu Kautiainen⁴ and Markku Kauppi², ¹Päijät-Häme Central Hospital, Lahti, Finland, ²Päijät-Häme Central Hospital, University of Helsinki, Lahti, Finland, ³Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ⁴Folkhälsan Research Center, Helsinki, Finland
Background/Purpose: Disorders of glucose metabolism are well-known major contributors to morbidity and mortality. Elevated serum uric acid (SUA), a key precursor of gout attacks, is…
Abstract Number: 2005 • ACR Convergence 2024
Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy
Puja Khanna¹, Vibeke Strand², Atul Singhal³, Herbert Baraf⁴, Rehan Azeem⁵, Wesley DeHaan⁶, Sheldon Leung⁵, Hugues Santin-Janin⁷, Aletta Falk⁸ and Alan Kivitz⁹, ¹University of Michigan, Ann Arbor, MI, ²Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ³Southwest Arthritis Research Group, Mesquite, TX, ⁴Center for Rheumatology and Bone Research, Wheaton, MD, ⁵Sobi Inc., Waltham, MA, ⁶Sobi, Inc, Waltham, MA, ⁷Sobi, BETTENDORF (68560), France, ⁸Sobi, Stockholm, Sweden, ⁹Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: SEL-212 is a once-monthly, investigational, two-component infusion therapy consisting of pegadricase (SEL-037, a pegylated uricase) and immune-tolerizing nanoparticles containing sirolimus (SEL-110), for the treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].